Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Endocrine Therapy vs Chemotherapy in HR+/HER2- Breast Cancer
NCT05755581Phase 1Unknown
- Sponsor
- Sohag University
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of goserelin and tamoxifen in breast cancer (2 arms), sponsored by Sohag University. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
goserelintamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05755581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755581.